Capricor Therapeutics Options Show Significant Volume Activity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PFE?
Source: NASDAQ.COM
- Surge in Options Volume: Capricor Therapeutics Inc (Ticker: CAPR) has seen an options trading volume of 4,798 contracts today, equating to approximately 479,800 shares, indicating a significant activity level at 46.1% of its average daily trading volume over the past month.
- Strike Price Interest: Notably, the $7 strike call option expiring on January 21, 2028, has garnered high trading volume with 3,002 contracts traded today, representing about 300,200 underlying shares of CAPR, reflecting strong market interest in this strike price.
- Disney Options Activity: Concurrently, Walt Disney Co (Ticker: DIS) recorded an options trading volume of 52,668 contracts today, representing approximately 5.3 million shares, or about 45.2% of its average daily trading volume over the past month, showcasing significant market attention.
- Strike Price Analysis: The $101 strike call option expiring on March 6, 2026, for DIS has also shown notable activity with 3,278 contracts traded today, representing around 327,800 shares, indicating investor optimism regarding this strike price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.050
Low
24.00
Averages
28.56
High
35.00
Current: 27.050
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Dividend Safety Faces Challenges Amid High Payout Ratio
- Payout Ratio Exceeds 100%: Pfizer's payout ratio has surpassed 100% again, indicating potential risks for its quarterly dividend of $0.43, especially as the company reports negative earnings per share.
- Profitability Impacted: In its Q4 2025 report, Pfizer showed an EPS of negative $0.29 primarily due to $4.4 billion in impairment charges, although its full-year EPS of $1.36 reflects a decline from the previous year.
- Cash Flow Pressure: With free cash flow at $9.1 billion and dividend payments nearing $9.8 billion, Pfizer faces financial strain in maintaining its dividend, which could hinder future growth investments.
- Market Uncertainty: While Pfizer's financials appear better due to non-cash impairment charges, the uncertainty surrounding its future business performance suggests that risk-averse investors may want to explore safer income investments.
See More
Olema Pharmaceuticals Stock Declines Following Clinical Trial Setback
- Clinical Trial Setback: Olema Pharmaceuticals' phase 3 study of giredestrant combined with palbociclib failed to achieve a statistically significant improvement in progression-free survival compared to letrozole plus palbociclib, resulting in bearish pressure on the stock as investors express concerns over product prospects.
- Price Trend Analysis: Currently trading at $17.14, Olema's stock is 26.2% below its 20-day simple moving average and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term, prompting investors to monitor shifts in market sentiment.
- Long-term Performance vs. Current Positioning: Despite a remarkable 294.05% increase in share price over the past 12 months, the stock is now closer to its 52-week lows, suggesting a weakening market confidence in future growth and potential risks of a pullback.
- Analyst Ratings and Price Targets: Despite facing short-term pressures, Olema's stock retains a Buy rating with an average price target of $37.33, reflecting analysts' confidence in its long-term potential, especially as several firms have recently raised their price targets.
See More
Pfizer and Eli Lilly's Strategic Moves in AI Healthcare
- Pfizer's AI Utilization: Pfizer has been leveraging AI in the development of its COVID-19 vaccine Comirnaty and plans to expand its AI applications in drug discovery, commercial operations, and manufacturing optimization; despite facing patent cliffs and competitive pressures, AI integration is expected to reduce costs and enhance R&D efficiency.
- Clinical Advancements: Pfizer is advancing several clinical candidates into phase 3 studies, including MET-097i for weight loss and an investigational cancer drug PF'4404; while a rapid business rebound may be unlikely, long-term improvements in R&D could yield positive outcomes.
- Eli Lilly's Supercomputer: Eli Lilly has built the most powerful supercomputer in the pharmaceutical industry with Nvidia's assistance, aimed at enhancing its drug development capabilities, and has established an AI innovation lab to optimize drug discovery and development processes, further solidifying its leadership in the fast-growing weight loss market.
- Market Performance and Outlook: Eli Lilly's revenue growth significantly outpaces its peers, particularly with its weight loss drug Zepbound becoming the world's best-seller; as it continues to invest in AI, the company's competitive edge in the healthcare sector is expected to strengthen further.
See More
Pfizer's Tilrekimig Phase 2 Study Shows Positive Results
- Clinical Trial Success: Pfizer's trispecific antibody tilrekimig met its primary endpoint in Phase 2, showing a statistically significant increase in participants achieving a 75% or greater reduction in eczema area and severity compared to placebo, indicating its potential in treating atopic dermatitis.
- Accelerated Phase 3 Development: Pfizer plans to expedite tilrekimig to Phase 3, with a pivotal study in atopic dermatitis set to begin in 2026, aiming to provide more effective treatment options and further solidify Pfizer's leadership in immunotherapy.
- Multiple Indication Potential: As a potentially first-in-class drug, tilrekimig targets various chronic Type 2 inflammatory conditions, including atopic dermatitis, asthma, and COPD, showcasing broad clinical development prospects that could redefine existing treatment standards.
- Clinical Development Strategy: Pfizer is conducting a two-stage Phase 2 study, targeting participants who have previously received biologic treatments and those receiving ompekimig, demonstrating the company's ongoing commitment to innovation and research in the inflammation and immunology space.
See More
Surge in Oil Prices Triggers Market Turmoil
- Oil Price Surge: U.S. crude futures have surged above $100 per barrel for the first time since mid-2022, driven by Iran's threats to close the Strait of Hormuz, with a staggering 35.6% increase last week marking the largest weekly gain in futures history, which has directly impacted the stock market, leading to the Dow's worst week in nearly a year.
- Economic Pressure Intensifies: The rising oil prices have prompted Democrats to frame the conflict as a catalyst for increased living costs, potentially affecting the upcoming midterm elections negatively, while Republicans hope for a swift resolution to avoid economic fallout, highlighting the intersection of politics and economics.
- FDA Leadership Change: Vinay Prasad, the FDA's vaccine chief, announced his resignation effective at the end of April following widespread criticism of his decisions from the biotech and pharmaceutical sectors, illustrating the challenges and pressures regulatory bodies face in managing public health crises.
- Changing Canadian Consumption Trends: Canadians continue to boycott U.S. goods, with data indicating a shift towards domestic brands and increased local tourism spending, a trend that could significantly impact Canada's GDP and inflation rates in the long term.
See More
Bristol Myers Squibb Highlights from 2025 Earnings Report
- Revenue Growth: Bristol Myers Squibb's Q4 2025 revenue increased by 1% year-over-year to $12.5 billion, despite a nearly 24% drop in net income to $2.6 billion, indicating a balance between growth and decline.
- New Drug Application Progress: The FDA has accepted Bristol Myers Squibb's new drug application for iberdomide for multiple myeloma, marking a significant advancement in the company's innovative drug development that could provide new revenue streams in the future.
- Growth Portfolio Performance: While the legacy portfolio's revenue fell by 15% to $5.1 billion, the growth portfolio, particularly the cancer drug Opdivo, saw a 16% increase to $7.4 billion, showcasing the company's strong performance in new drug areas.
- Optimistic Future Outlook: Management expects 2026 revenue to range between $46 billion and $47.5 billion, with adjusted net income of $6.05 to $6.35 per share, both exceeding analyst expectations, reflecting the company's confidence in future growth.
See More
Pfizer's Dividend Safety Faces Challenges Amid High Payout Ratio
- Payout Ratio Exceeds 100%: Pfizer's payout ratio has surpassed 100% again, indicating potential risks for its quarterly dividend of $0.43, especially as the company reports negative earnings per share.
- Profitability Impacted: In its Q4 2025 report, Pfizer showed an EPS of negative $0.29 primarily due to $4.4 billion in impairment charges, although its full-year EPS of $1.36 reflects a decline from the previous year.
- Cash Flow Pressure: With free cash flow at $9.1 billion and dividend payments nearing $9.8 billion, Pfizer faces financial strain in maintaining its dividend, which could hinder future growth investments.
- Market Uncertainty: While Pfizer's financials appear better due to non-cash impairment charges, the uncertainty surrounding its future business performance suggests that risk-averse investors may want to explore safer income investments.
See More
Olema Pharmaceuticals Stock Declines Following Clinical Trial Setback
- Clinical Trial Setback: Olema Pharmaceuticals' phase 3 study of giredestrant combined with palbociclib failed to achieve a statistically significant improvement in progression-free survival compared to letrozole plus palbociclib, resulting in bearish pressure on the stock as investors express concerns over product prospects.
- Price Trend Analysis: Currently trading at $17.14, Olema's stock is 26.2% below its 20-day simple moving average and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term, prompting investors to monitor shifts in market sentiment.
- Long-term Performance vs. Current Positioning: Despite a remarkable 294.05% increase in share price over the past 12 months, the stock is now closer to its 52-week lows, suggesting a weakening market confidence in future growth and potential risks of a pullback.
- Analyst Ratings and Price Targets: Despite facing short-term pressures, Olema's stock retains a Buy rating with an average price target of $37.33, reflecting analysts' confidence in its long-term potential, especially as several firms have recently raised their price targets.
See More
Pfizer and Eli Lilly's Strategic Moves in AI Healthcare
- Pfizer's AI Utilization: Pfizer has been leveraging AI in the development of its COVID-19 vaccine Comirnaty and plans to expand its AI applications in drug discovery, commercial operations, and manufacturing optimization; despite facing patent cliffs and competitive pressures, AI integration is expected to reduce costs and enhance R&D efficiency.
- Clinical Advancements: Pfizer is advancing several clinical candidates into phase 3 studies, including MET-097i for weight loss and an investigational cancer drug PF'4404; while a rapid business rebound may be unlikely, long-term improvements in R&D could yield positive outcomes.
- Eli Lilly's Supercomputer: Eli Lilly has built the most powerful supercomputer in the pharmaceutical industry with Nvidia's assistance, aimed at enhancing its drug development capabilities, and has established an AI innovation lab to optimize drug discovery and development processes, further solidifying its leadership in the fast-growing weight loss market.
- Market Performance and Outlook: Eli Lilly's revenue growth significantly outpaces its peers, particularly with its weight loss drug Zepbound becoming the world's best-seller; as it continues to invest in AI, the company's competitive edge in the healthcare sector is expected to strengthen further.
See More
Pfizer's Tilrekimig Phase 2 Study Shows Positive Results
- Clinical Trial Success: Pfizer's trispecific antibody tilrekimig met its primary endpoint in Phase 2, showing a statistically significant increase in participants achieving a 75% or greater reduction in eczema area and severity compared to placebo, indicating its potential in treating atopic dermatitis.
- Accelerated Phase 3 Development: Pfizer plans to expedite tilrekimig to Phase 3, with a pivotal study in atopic dermatitis set to begin in 2026, aiming to provide more effective treatment options and further solidify Pfizer's leadership in immunotherapy.
- Multiple Indication Potential: As a potentially first-in-class drug, tilrekimig targets various chronic Type 2 inflammatory conditions, including atopic dermatitis, asthma, and COPD, showcasing broad clinical development prospects that could redefine existing treatment standards.
- Clinical Development Strategy: Pfizer is conducting a two-stage Phase 2 study, targeting participants who have previously received biologic treatments and those receiving ompekimig, demonstrating the company's ongoing commitment to innovation and research in the inflammation and immunology space.
See More
Surge in Oil Prices Triggers Market Turmoil
- Oil Price Surge: U.S. crude futures have surged above $100 per barrel for the first time since mid-2022, driven by Iran's threats to close the Strait of Hormuz, with a staggering 35.6% increase last week marking the largest weekly gain in futures history, which has directly impacted the stock market, leading to the Dow's worst week in nearly a year.
- Economic Pressure Intensifies: The rising oil prices have prompted Democrats to frame the conflict as a catalyst for increased living costs, potentially affecting the upcoming midterm elections negatively, while Republicans hope for a swift resolution to avoid economic fallout, highlighting the intersection of politics and economics.
- FDA Leadership Change: Vinay Prasad, the FDA's vaccine chief, announced his resignation effective at the end of April following widespread criticism of his decisions from the biotech and pharmaceutical sectors, illustrating the challenges and pressures regulatory bodies face in managing public health crises.
- Changing Canadian Consumption Trends: Canadians continue to boycott U.S. goods, with data indicating a shift towards domestic brands and increased local tourism spending, a trend that could significantly impact Canada's GDP and inflation rates in the long term.
See More
Bristol Myers Squibb Highlights from 2025 Earnings Report
- Revenue Growth: Bristol Myers Squibb's Q4 2025 revenue increased by 1% year-over-year to $12.5 billion, despite a nearly 24% drop in net income to $2.6 billion, indicating a balance between growth and decline.
- New Drug Application Progress: The FDA has accepted Bristol Myers Squibb's new drug application for iberdomide for multiple myeloma, marking a significant advancement in the company's innovative drug development that could provide new revenue streams in the future.
- Growth Portfolio Performance: While the legacy portfolio's revenue fell by 15% to $5.1 billion, the growth portfolio, particularly the cancer drug Opdivo, saw a 16% increase to $7.4 billion, showcasing the company's strong performance in new drug areas.
- Optimistic Future Outlook: Management expects 2026 revenue to range between $46 billion and $47.5 billion, with adjusted net income of $6.05 to $6.35 per share, both exceeding analyst expectations, reflecting the company's confidence in future growth.
See More
